Type | Trade name | Indication | Year licensed | Administration |
---|---|---|---|---|
Intravenous immunoglobulins | ||||
Intravenous Ig (IVIG) | Asceniv®; Bivigam®; Carimune®; Flebogamma® DIF; Gammagard ®liquid, S/D; Gammaplex®; Gamunex-C®; Intratect®; Kiovig®; Nanogam®;  Octagam®; Panzyga®; Privigen® | Primary immune deficiencies, other | Various (FDA and or EMA) | i.v. |
Cutaquig®; Cuvitru®; Gammanorm®; Hizentra®; HyQvia®; Evogam®; Vivaglobin® Xembify® | Primary immune deficiencies, other | Various (FDA and or EMA) | i.m./s.c. | |
Strimvelis®; | ADA-SCID | 2016 (EMA) | i.v. | |
Hyperimmune globulins | ||||
Hepatitis A-Ig | HNIG; GamaSTAN® S/D; Beriglobin® P | PrEP and PEP hepatitis A virus | Various (FDA, EMA or other) | i.m. |
Hepatitis B-Ig | Zutectra®; HepaGam B®; HyperHEP B®; Nabi-HB®; Hepatect® CP | PrEP and PEP hepatitis B virus | Various (FDA, EMA or other) | i.v. /i.m. |
Varicella-zoster Ig | VARIZIG®; Zoster Ig-VF; | PEP Varicella Zoster Virus | Various (FDA, EMA or other) | i.m. |
Tetanus Ig | HTIG; Tetagam® P; Tetanus Ig-VF IM; HyperTET® S/D | PEP tetanus | Various (FDA, EMA or other) | i.m. |
Rabies Ig | HRIG; Berirab® P; Imogam® Rabies; Rabies-HT; Kedrab®; Hyperrab® | PEP rabies | Various (FDA, EMA or other) | s.c. |
Cytomegalovirus Ig | Megalotect®; Cytogam® | PrEP cytomegalovirus | Various (FDA, EMA or other) | i.v. |
Anthrax Ig | Anthrasil® | Treatment of inhalational anthrax | 2015 (FDA) | i.v. |
Botulin Ig | BabyBIG® | Treatment of infant botulism caused by toxin types A and B | 2003 (FDA) | i.v. |
Vaccinia Ig | none | Treatment of vaccinia, PEP variola | 2010 (FDA) | i.v. |
Hyperimmune sera | ||||
Diphtheria antitoxin (equine) | DAT | Treatment of symptomatic diphtheria | unlicensed | i.v. |
Botulism Antitoxin (equine) | Botulism Antitoxin Bivalent (Equine) Types A and B; BAT (Heptavalent (A, B, C, D, E, F, G) | Treatment of symptomatic botulism | 2005 (FDA)/ 2013 (FDA) | i.v. |
Monoclonal antibodies | ||||
Palivizumab | Synagis® | PrEP RSV | 1998 (FDA)/1999 (EMA) | i.m. |
Raxibacumab | none | PEP, and treatment of anthrax | 2012 (FDA)/2014 (EMA, os) | i.v. |
Obiltoxaximab | Anthim® | PEP, and treatment of anthrax | 2016 (FDA)/2020 (EMA) | i.v. |
Bezlotoxumab | Zinplava® | PrEP C. difficile | 2016 (FDA)/2017 (EMA) | i.v. |
Ibalizumab | Trogarzo® | Treatment of HIV-1 | 2018 (FDA)/2019 (EMA) | i.v. |
Docaravimab/miromavimab | TwinRabâ„¢/RabiMabsâ„¢ | PEP rabies | 2019 (FDA, os) | s.c. |
Atoltivimab/maftivimab/odesivimab | Inmazeb® | Treatment of Ebola | 2018 (EMA, os); 2020 (FDA, os) | i.v. |
Porgaviximab | Zmapp® | Treatment of Ebola | 2015 (EMA os, 2021 withdrawn) | i.v. |
Ansuvimab | Ebangaâ„¢ | Treatment of Ebola | 2020 (FDA) | i.v. |
Casirivimab/Imdevimab | Ronapreve® | PrEP, PEP, treatment of COVID | 2020 (FDA, 2022)/2021 (EMA) | s.c./i.v. |
Sotrovimab | Xevudy | Treatment of COVID | 2021 (FDA, 2022)/2021 (EMA) | i.v. |
Bamlanivimab/etesevimab | none | PEP, treatment of COVID | 2021 (FDA, 2022) | i.v. |
Regdanvimab | Regkironaâ„¢ | Treatment of COVID | 2021 (EMA) | i.v. |
Tixagevimab/cilgavimab | Evusheldâ„¢ | PrEP COVID | 2021 (FDA)/2022 (EMA) | i.m. |
Tocilizumab | RoActemra®/Tyenne® | Treatment of COVID | 2021(FDA)/2021(EMA); EMA(2023) | i.v./s.c. |
Nirsevimab | Beyfortus® | PrEP RSV | 2022 (EMA) | i.m. |